Fecal Microbiota Transplantation Clinical Trial
— PROFITOfficial title:
Profiling Fecal Samples to Optimize Selection of Stool Donors for Fecal Microbiota Transplantation
Verified date | March 2020 |
Source | Assistance Publique - Hôpitaux de Paris |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Fecal microbiota transplantation (FMT) represents a promising therapeutic in numerous clinical situations associated with dysbiosis. Today, this procedure is recommended in patients with recurrent Clostridioides difficile infections but beneficial effects of FMT have also been described in other diseases associated with intestinal dysbiosis …. A donor effect which could be related to the inter-individual variability of microbiota and microbiome leading to specific metabolic capacities may influence the efficacy of the procedure.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | June 2021 |
Est. primary completion date | June 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Age = 18 years 2. Healthy volunteers 3. Participant having been informed of the study and having sign a consent to participation 4. Patient affiliated with a social security or beneficiary of such a social protection Exclusion Criteria: 1. Person subject to legal protection (guardianship, trusteeship, etc.) 2. Chronic disease that can alter the intestinal microbiota: cancer or malignant disease, bowel disease, diabetes, hypertension, hypercholesterolemia, .... 3. Presence in the 1st degree family of one of the chronic diseases mentioned above 4. Blood in stools 5. Chronic drug treatment likely to alter the intestinal microbiota 6. Travel to a tropical country in the last 3 months or extended stay (> 3 months) for less than 1 year 7. Hospitalization abroad (> 24h) in the last 12 months 8. Hospitalization abroad (> 24h) of a family member living under the same roof during the last 12 months 9. Medical consultation in the last 3 months (other than administrative) 10. Contact with a person with an infectious or contagious disease for more than 3 months 11. Digestive disorders / febrile gastroenteritis (diarrhea with fever) in the last 3 months 12. Febrile illnesses for more than 3 months 13. Antibiotic treatment in the last 3 months 14. Treatment with PPIs in the last 3 months |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris | Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement, University of Paris 5 - Rene Descartes |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Dosage of fecal samples with search for differentiated fecal profiles. | 16S genomic analysis of microbiota will be performed for the evaluation of alpha and beta diversities of microbiota.
Results will be aggregated to define differentiated faecal profiles in healthy volunteers. |
At 12 months | |
Secondary | Dosage of fecal biomarkers with search for differentiated fecal profiles. | Fecal biomarkers such as calprotectin will be dosed. Results will be aggregated to define differentiated faecal profiles in healthy volunteers. | At 12 months | |
Secondary | Quantification of colonic inflammation in mouse model. | The quantification of colonic inflammation by myeloperoxidase assay using a sandwich ELISA enzyme-linked immunosorbent assay.
Mouse model : authorization APAFlS#7600-20l60620l6336853 v3 |
At 15 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT04436874 -
Fecal Microbiota Transplantation in the Treatment of Inflammatory Bowel Disease
|
N/A | |
Recruiting |
NCT03325855 -
Fecal Microbiota Transplant National Registry
|
||
Completed |
NCT06162702 -
Clinical Study of Fecal Microbiota Transplantation in the Treatment of Small Intestinal Bacterial Overgrowth (SIBO)
|
N/A | |
Active, not recruiting |
NCT05607745 -
Dietary Counseling Coupled With FMT in the Treatment of Obesity and NAFLD - the DIFTOB Study
|
N/A | |
Completed |
NCT05121285 -
Distribution of FMT After Delivery by · Lower GI Endoscopy vs Enema With and Without Positioning of the Patient
|
N/A | |
Active, not recruiting |
NCT05917379 -
The Safety and Efficacy of FMT in Patients With CID
|
Phase 1/Phase 2 | |
Recruiting |
NCT02318147 -
Fecal Microbiota Transplantation for Pancreatitis With Infectious Complications(FMTPIC)
|
Phase 1 | |
Completed |
NCT02318134 -
Fecal Microbiota Transplantation for Pancreatitis
|
Phase 2 | |
Completed |
NCT05035784 -
RCE With FMT in the Treatment of Childhood Constipation
|
N/A | |
Active, not recruiting |
NCT04173208 -
Main Trial of the Cesarean Section and Intestinal Flora of the Newborn Study
|
N/A | |
Terminated |
NCT04577729 -
The IRMI-FMT Trial
|
N/A | |
Not yet recruiting |
NCT02435160 -
The Study of Efficacy and Mechanism in Fecal Microbiota Transplantation in the Treatment of Ulcerative Colitis
|
Phase 2/Phase 3 | |
Recruiting |
NCT04837313 -
Efficacy and Safety of Fecal Microbiota Transplantation in the Treatment of Parkinson's Disease With Constipation
|
N/A | |
Recruiting |
NCT04861649 -
Metabonomics of COPD and Transplanting of Faecal Bacteria in the Treatment of Its Malnutrition
|
N/A | |
Recruiting |
NCT05821010 -
Synbiotics and Fecal Microbiota Transplantation to Treat Non-Alcoholic Steatohepatitis
|
Phase 2 | |
Recruiting |
NCT05273255 -
Fecal Microbiota Transplantation in Patients With Malignancies Not Responding to Cancer Immunotherapy
|
N/A | |
Not yet recruiting |
NCT05253222 -
Methodology and Clinical Value of RIT in Intestinal Obstructive Diseases Mediated by Colonic TET
|
N/A | |
Recruiting |
NCT04285424 -
FMT for Steroid Resistant Gut Acute GVHD
|
Early Phase 1 | |
Withdrawn |
NCT03527056 -
Pilot Study Using Oral Capsule FMT to Decolonize GI CRE
|
Early Phase 1 | |
Recruiting |
NCT03018613 -
Fecal Microbiota Transplantation for Chronic Functional Constipation
|
Phase 1/Phase 2 |